<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004318" GROUP_ID="COLOCA" ID="006401091622542442" MERGED_FROM="" MODIFIED="2008-11-10 15:05:54 +0100" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: Prolonged thromboprophylaxis in abdominal surgery&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 13:19:26 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="047" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.2">
<COVER_SHEET MODIFIED="2008-11-10 15:05:54 +0100" MODIFIED_BY="Henning Keinke Andersen">
<TITLE MODIFIED="2008-09-23 20:15:16 +0200" MODIFIED_BY="[Empty name]">Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery</TITLE>
<CONTACT MODIFIED="2008-11-10 15:05:54 +0100" MODIFIED_BY="Henning Keinke Andersen"><PERSON ID="12874" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Morten Schnack</FIRST_NAME><LAST_NAME>Rasmussen</LAST_NAME><POSITION>Senior Registrar</POSITION><EMAIL_1>msr@dadlnet.dk</EMAIL_1><ADDRESS><DEPARTMENT>Surgical gastroenterology dept. K</DEPARTMENT><ORGANISATION>H:S Bispebjerg Hospital</ORGANISATION><ADDRESS_1>23 Bispebjeg Bakke</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2400</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-10 15:05:54 +0100" MODIFIED_BY="Henning Keinke Andersen"><PERSON ID="12874" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Morten Schnack</FIRST_NAME><LAST_NAME>Rasmussen</LAST_NAME><POSITION>Senior Registrar</POSITION><EMAIL_1>msr@dadlnet.dk</EMAIL_1><ADDRESS><DEPARTMENT>Surgical gastroenterology dept. K</DEPARTMENT><ORGANISATION>H:S Bispebjerg Hospital</ORGANISATION><ADDRESS_1>23 Bispebjeg Bakke</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2400</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="FBBD825E82E26AA200C04FC1E45C9599" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lars</FIRST_NAME><MIDDLE_INITIALS>Nannestad</MIDDLE_INITIALS><LAST_NAME>Jørgensen</LAST_NAME><POSITION>Senior consultant</POSITION><EMAIL_1>larsnjorgensen@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgical Gastroenterology K</DEPARTMENT><ORGANISATION>Bispebjerg Hospital</ORGANISATION><ADDRESS_1>Bispebjerg Bakke 23</ADDRESS_1><CITY>Copenhagen NV</CITY><ZIP>2400 </ZIP><COUNTRY CODE="DK">Denmark</COUNTRY></ADDRESS></PERSON><PERSON ID="6565" ROLE="AUTHOR"><FIRST_NAME>Peer</FIRST_NAME><LAST_NAME>Wille-Jørgensen</LAST_NAME><POSITION>Consultant Surgeon</POSITION><EMAIL_1>pwj01@bbh.regionh.dk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgical Gastroenterology K</DEPARTMENT><ORGANISATION>Bispebjerg Hospital</ORGANISATION><ADDRESS_1>Bispebjerg Bakke 23</ADDRESS_1><CITY>Copenhagen NV</CITY><ZIP>DK-2400</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3531 3086</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-10 15:05:54 +0100" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Minor update: 05/09/02&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 13:39:57 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="10" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="30" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="8" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-07 13:19:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-02 18:14:36 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-02 18:14:27 +0100" MODIFIED_BY="[Empty name]">Prolonged administration of low molecular weight heparin lowers the number of blood clots in the lower limbs after operation in the abdomen or pelvis</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-02 18:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>Patients subjected to major surgery of the abdomen are at considerable risk of developing blood clots in the veins of the lower limbs. These clots may detach and develop clots in the lungs and cause sudden death. Clots in the limbs may impaire the venous function leading to a life-long tendency to swollen legs and leg ulceration. In order to avoid these complications patients are often offered protective medicine during the first week after surgery, but patients are probably at risk of developing clots up to one month after surgery. This review suggests that prophylaxis should be administered for at least one month after surgery.
<BR/>

</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-02 18:14:23 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Major abdominal and pelvic surgery carries a high risk of venous thromboembolism (VTE). The efficacy of thromboprophylaxis with low-molecular weight heparin (LMWH) administered during the in-hospital period is well documented, but the optimal duration of thromboprophylaxis after surgery remains controversial. Some studies suggest that patients undergoing major abdominal surgery benefit from prolongation of the thromboprophylaxis to 1 month after surgery. No systematic review on prolonged thromboprophylaxis after major abdominal or pelvic surgery has been published.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-28 13:54:42 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of prolonged thromboprophylaxis with LMWH for at least 1 month after abdominal or pelvic surgery with thromboprophylaxis administered during the in-hospital period only in preventing late VTE.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-28 14:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>Electronic searches were performed January 2008 in the Medline, Embase, Lilacs, and the Cochrane Central Register of Controlled Trials. Abstract books from major congresses addressing thromboembolism were hand searched, as were reference lists from studies of relevance. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-10-28 13:55:13 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed both randomised and non-randomised controlled clinical trials comparing prolonged thromboprophylaxis with any anti-thrombotic agent with placebo and/or thromboprophylaxis during the admission period only. The patient population in the trials were patients undergoing abdominal or pelvic surgery. The outcome measures included VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)) as assessed by objective means (ascending bilateral venography, ultrasonography, pulmonary ventilation/perfusion scintigraphy, spiral CT scan or autopsy). Studies exclusively reporting on clinical diagnosis of VTE, without objective confirmation were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-09-23 21:02:13 +0200" MODIFIED_BY="[Empty name]">
<P>The identification of studies and data extraction were performed by the authors. Outcomes were VTE (DVT or PE) assessed by objective means. Safety outcome were defined as bleeding complications and mortality within 3 months after surgery. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-02 18:14:02 +0100" MODIFIED_BY="[Empty name]">
<P>The search exclusively detected trials evaluating prolonged thromboprophylaxis with LMWH as compared to control or placebo. 133 studies were found in the searches, of which only 4 were found eligible for inclusion, and 129 were excluded. The incidence of overall VTE after major abdominal or pelvic surgery was 14.3% (95% confidence interval 11.2% - 17.8%) in the control group as compared to 6.1% (95% CI 4.0% - 8.7%) in the patients receiving out-of-hospital LMWH. This difference was statistically significant, Peto Odds Ratio 0.41 (95% CI 0.26 -0.63), P &lt; 0.0005. Prolonged thromboprophylaxis with LMWH was also associated with a statistically significant reduction of even the incidence of symptomatic VTE from 1.7% (95% CI 0.8% - 3.4%) in the control group to 0.2 % (95% CI 0.0% - 1.2%) in patients receiving prolonged thromboprophylaxis, Peto Odds ratio 0.22 (95% CI 0.06 -0.80), P = 0.02. The respective incidence of bleeding in the control and LMWH group were 3.7% (95% CI 2.4% -5.5%) and 4.1% (95% CI 2.7% - 6.0%), Peto Odds ratio 1.11 (95% CI 0.62 - 1.97), P = 0.73. There was no significant heterogeneity detected as regards to outcome parameters reported in the included trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-02 18:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged thromboprophylaxis with LMWH significantly reduces the risk of VTE compared to thromboprophylaxis during hospital admittance only, without increasing bleeding complications after major abdominal or pelvic surgery.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-04 16:39:57 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-03 12:05:53 +0100" MODIFIED_BY="[Empty name]">
<P>Abdominal surgery leads to a hypercoagulable state, indicating an increased risk for DVT (<LINK REF="REF-Iversen-2002" TYPE="REFERENCE">Iversen 2002</LINK>). The activation of the coagulation system last for at least 14 days (<LINK REF="REF-Galster-2000" TYPE="REFERENCE">Galster 2000</LINK>) and unpublished data suggests that patients remain in a hypercoagulable state for at least one month after surgery. Dahl et al. reported that discontinuation of thromboprophylaxis one week after hip surgery resulted in a second wave of coagulation and fibrinolysis activation (<LINK REF="REF-Dahl-1995" TYPE="REFERENCE">Dahl 1995</LINK>). Administration of extended thromboprophylaxis with LMWH lowers the markers of coagulation (<LINK REF="REF-Arnesen--2003" TYPE="REFERENCE">Arnesen 2003</LINK>). After major abdominal surgery a similar activated condition lasted until after discharge and was significantly more pronounced for patients with malignant compared to benign disease (<LINK REF="REF-Rahr-1994" TYPE="REFERENCE">Rahr 1994</LINK>).</P>
<P>Patients undergoing major abdominal or pelvic surgery are at increased risk of developing postoperative venous thromboembolic complications (VTE). The incidence of deep vein thrombosis (DVT) following abdominal surgery in the absence of thromboprophylaxis is 19 to 29% in high risk patients (<LINK REF="REF-Geerts-2001" TYPE="REFERENCE">Geerts 2001</LINK>). Several methods to reduce VTE have been implemented clinically. Thromboprophylaxis with unfractionated or low-molecular weight heparin (LMWH) administered for the first postoperative week in general surgical patients reduces the incidence of VTE (<LINK REF="REF-Geerts-2001" TYPE="REFERENCE">Geerts 2001</LINK>).<BR/>
</P>
<P>Prospective cohort studies have revealed an incidence of postoperative DVT as high as 25% four to six weeks after surgery (<LINK REF="REF-S_x00f8_rensen-1990" TYPE="REFERENCE">Sørensen 1990</LINK>, <LINK REF="REF-Scurr-1988" TYPE="REFERENCE">Scurr 1988</LINK>, <LINK REF="REF-Clarke_x002d_Pearson-1984" TYPE="REFERENCE">Clarke-Pearson 1984</LINK>), and a 0.13 - 0.63% incidence of pulmonary embolism (PE) of (<LINK REF="REF-Kiil-1978" TYPE="REFERENCE">Kiil 1978</LINK>, <LINK REF="REF-Huber-1992" TYPE="REFERENCE">Huber 1992</LINK>). A small, randomised study including general surgical patients showed a non-significant reduction in the incidence of DVT as assessed by bilateral venography 28 days after surgery, following four weeks versus one week of thromboprophylaxis with a LMWH (<LINK REF="STD-Lausen-1998" TYPE="STUDY">Lausen 1998</LINK>). A larger double-blind multicentre study with a comparable design reported a significant reduction of DVT in patients with abdominal or pelvic cancer after prolongation of prophylactic administration of LMWH (<LINK REF="STD-Bergqvist-2002" TYPE="STUDY">Bergqvist 2002</LINK>). The optimal duration of thromboprophylaxis in general surgery remains controversial.<BR/>The efficacy of unfractionated heparin and LMWH in general surgery is comparable but thromboprophylaxis with LMWH allows once daily injection and carries a lesser risk of heparin-induced thrombocytopenia (<LINK REF="REF-J_x00f8_rgensen-1993" TYPE="REFERENCE">Jørgensen 1993</LINK>).<BR/>The efficacy of prolonged thromboprophylaxis in patients undergoing major abdominal or pelvic surgery has not previously been systematically reviewed.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-02 18:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>The purpose of this systematic review was to evaluate the efficacy and safety of prolonged thromboprophylaxis with different prophylactic methods in preventing late VTE when compared to thromboprophylaxis administered during the first week after surgery.</P>
<P>Late VTE was defined as VTE occurring from the 7th post-operative day and until 3 months postoperatively.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-03 13:20:50 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-03 13:19:08 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-28 14:12:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised or non-randomised controlled clinical trials comparing prolonged thromboprophylaxis interventions with in-hospital prophylaxis and later placebo or no treatment were considered.<BR/>Objective diagnostic methods were mandatory for the screening in all patients. Studies with symptomatic outcome measures were included if objectively confirmed.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-03 13:19:08 +0100" MODIFIED_BY="[Empty name]">
<P>Patients undergoing general abdominal or pelvic surgery for cancer or benign disease. The surgical procedures included both laparotomies and laparoscopies..</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Trials reporting the use of the following interventions were considered:</P>
<P>A: LMWH (different doses)<BR/>B: Unfractionated heparin (5,000 IU s.c. b.i.d or t.i.d)<BR/>C: Mechanical methods (graded compression stockings, sequential compression devices)<BR/>D: Vitamin K antagonists (phenprocoumon or acenocoumarol)</P>
<P>The prophylactic intervention to patients allocated to prolonged thromboprophylaxis should be continued for at least 14 days after surgery.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-02 18:11:28 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcomes included the incidence of DVT, PE or fatal PE within 30 days after surgery and the postoperative 3 months mortality rate. The efficacy outcome includes both symptomatic and asymptomatic DVT and PE.VTE was to be verified by a mandatory objective test. These included venography, ultrasound/Doppler examination, ventilation-perfusion lung scintigraphy, spiral CT scan or autopsy. The secondary outcomes were symptomatic VTE, verified by mandatory objective test, bleeding complications and mortality. Durring the analyses, it became apparent that mortality was an important outcome and were thus included as a secondary outcome. Bleeding complications were defined as major or minor bleeding according to the definition in the primary studies. Safety outcome measures were evaluated from reported transfusions requirements.</P>
<P>The evaluations of the outcomes should be blinded with regard to the prophylactic treatment given (assessor-blinded), if a double-blind method was not applied.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-28 14:19:22 +0100" MODIFIED_BY="[Empty name]">
<P>An electronic search was conducted January 2008, by an experienced trial search coordinator, in Pubmed from 1967, in Lilacs from 1967, in Embase from 1980 and the Cochrane Central Register of Controlled Trials. The general search strategy described by the Cochrane Colorectal Cancer Group was used in Medline and the Cochrane Central Register of Controlled Trials as well as a comparable search strategy in the Embase-search. A search for both randomised and non-randomised controlled clinical trials was done. The bibliography of each trial report were checked for additional references. Primary authors of RCTs were contacted, if necessary, for clarification of data. The reference-lists from major review articles from 1990 were scrutinized. All references from previously performed meta-analyses were crossed-checked with the other searches. The abstract books of the congresses arranged by The International Society on Thrombosis and Haemostasis as well as The Mediterranean League against Thrombosis were consulted back to 1976.</P>
<P>The general search strategy for the databases:</P>
<P>general surgery OR abdominal surgery<BR/>AND<BR/>thrombos* OR thromboem*<BR/>AND<BR/>prophylaxis OR prophylactic OR prevention<BR/>AND<BR/>prolonged OR long term OR duration OR late</P>
<P>The above search strategy were combined with the following to identify randomised controlled trials in Pubmed and Cancer lit:</P>
<P>1: Randomised-controlled-trial in PT<BR/>2: Randomised-controlled-trials<BR/>3: Random*<BR/>4: Double-blind-method<BR/>5: Single-blind-method<BR/>6: #1 OR #2 OR #3 OR #4 OR #5</P>
<P>The general search strategy were combined with the following to identify randomised controlled trials in Embase:</P>
<P>1: explode 'clinical trial' / all subheadings<BR/>2: explode 'controlled study' / all subheadings<BR/>3: 'randomisation-' / all subheadings<BR/>4: 'case-control-study' / all subheadings<BR/>5: #2 NOT #4<BR/>6: #1OR #3 OR #5<BR/>7: random* OR clin*<BR/>8: #6 OR #7</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-03 13:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>All identified studies were reviewed independently by the three authors, MSR, LNJ and PWJ, for possible inclusion, and consensus were obtained in cases where the reviewers disagreed on the validity of the study and/or data extraction. The studies were validated with regard to:</P>
<P>
<I>General patient characteristics: </I>
</P>
<P>
<I>Intervention characteristics:</I> methods of prolonged thromboprophylaxis and use of placebo or untreated control</P>
<P>
<I>Outcomes:</I> application of objective methods to confirm the diagnosis of VTE.</P>
<P>
<I>Methodological characteristics:</I> randomisation, concealment of allocation, blinding (patients, healthcare providers, data collectors, outcome assessors and data analysts), whether an intention-to-treat analysis (ITT) was conducted, outcome definition, definition of and completeness of follow-up, early stoppage of a trial</P>
<P>Retrospective studies were excluded.</P>
<P>
<BR/>The following data were extracted: type of prophylaxis, duration of thromboprophylaxis, type of VTE end point, total incidence of VTE including specific rates of DVT (total, proximal and distal) and PE (total and fatal) within 3 months after surgery, total mortality within 3 months, bleeding events, amounts of bleeding and total number of transfusions. Thrombi located in and above the popliteal vein were classified as a proximal DVT. Studies reporting on different types of LMWH were only entered into the same analysis if the dose of LMWH was found comparable in anti-Xa units (20 mg enoxaparin equalize 2500 anti-Xa units) and the control groups appeared uniform.
<BR/>
It was allowed, that the type of diagnostic objective measures differed across trials, as long as it was uniformly applied within the individual study to all patients.</P>
<P>Statistical analyses:<BR/>The results from each trial were entered into the RevMan Analyses version 4.2 . and analysed as binomial data for the VTE end point. The fixed effect model were used for the meta-analyses calculating Peto Odds Ratios unless statistical heterogeneity was present, then a random effects model was used. No comparisons across different trials between apparently equal groups were made because of the well-documented substantial inter-observer variation regarding the reported end points in various prophylactic trials, which substantially can influence the incidence of VTE (<LINK REF="REF-Wille_x002d_J_x00f8_rgensen-1992" TYPE="REFERENCE">Wille-Jørgensen 1992</LINK>). A sensitivity test of this meta-analysis was performed by exclusion of unpublished data.<BR/>The trials were checked for heterogeneity while conducting the analyses. Assessement for publication bias was considered, but a funnel-plot gives no meaning with so few included studies and was therefore omitted.</P>
<P>The protocol called for a multivariate analysis to find possible risk factors for late occurring VTE. However the published data were not sufficient to perform this analysis</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-04 16:39:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-04 16:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>The primary search performed revealed 132 studies, of which 94 were excluded by reviewing the title 38 were selected to be evaluated by the abstract, of these 5 met the inclusion criteria. 33 studies were excluded by the primary selection because they lacked inclusion of patients undergoing abdominal or pelvic surgery, did not address thromboprophylaxis beyond day 14 after surgery or were not clinical controlled trials. One trial were excluded as it was a double publication (<LINK REF="STD-Rasmussen-2003" TYPE="STUDY">Rasmussen 2003</LINK>), and one because it was a review (<LINK REF="STD-Rasmussen-2003a" TYPE="STUDY">Rasmussen 2003a</LINK>). In addition we found one trial by hand searching and only as an abstract presentation, and is thus reported as unpublished data (<LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>).<BR/>Thus, three RCTs published as papers and one RCT published as an abstract met the inclusion criteria of this review and were included in the meta-analysis (<LINK REF="STD-Bergqvist-2002" TYPE="STUDY">Bergqvist 2002</LINK>; <LINK REF="STD-Lausen-1998" TYPE="STUDY">Lausen 1998</LINK>; <LINK REF="STD-Rasmussen-2006" TYPE="STUDY">Rasmussen 2006</LINK>; <LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>). The trial of Bergqvist et al. was a double-blinded RCT, while the trials of Rasmussen et al. and Lausen et al. were open-labelled trials with blinded assessment of the venograms. The publication of Jorgensen et al. consisted of a meta-analysis of the material from the Lausen et al. trial and unpublished data from a double-blind RCT. Both of these trials were terminated prematurely due to lack of funding .The data from the Lausen et al. trial was entered in the present analysis once, thus the data obtained from the Jorgensen et al. study will be the unpublished data from that meta-analysis.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-02 18:18:52 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the individual studies are listed in the table of included studies.</P>
<P>Methodological quality of included studies/ Quality assessment.<BR/>All the trials defined an ITT analysis of the outcome data as those patients who entered the randomised phase of the study and had an evaluable efficacy end-point. None of the studies provided information of number of transfusions.</P>
<P>Lausen et al. trial:<BR/>Randomisation: Computer-generated allocation list</P>
<P>Concealment:Adequated with sealed envelopes.<BR/>Blinding: Open-label study with assessor-blinded evaluation of the venograms. Patients, healthcare providers and data-analyst were not blinded.</P>
<P>
<BR/>Patients characteristics: Patients undergoing major abdominal surgery or non cardiac thoracic surgery for either benign or malignant disease<BR/>ITT-analysis: Patients were included in the final analysis if they have reached an evaluable VTE end point (venogram or objective verification of symptomatic VTE)<BR/>Completeness of follow-up: There was no defined follow-up period.</P>
<P>Early stoppage of a trial: The study was terminated prematurely due to lack of funding.<BR/>Outcome definition: All patients were scheduled for bilateral venography. An adequate definition of VTE was described int he paper. No definition of bleeding complications was given in the paper, but bleeding episodes were described.<BR/>
<BR/>Bergqvist et al. trial:<BR/>Randomisation: Not described in the paper</P>
<P>Concealment: Not described in the paper.<BR/>Blinding: Placebo-controlled double blind study. Patiens, healthcare provides, data collectors, outcome assessors and data analysts were blinded.</P>
<P>
<BR/>Patients characteristics: Patients undergoing major abdominal or pelvic surgery for either benign or malignant disease<BR/>ITT-analysis: Patients was included in the final analysis if they have reached a evaluable VTE end point (venogram or objective verification of symptomatic VTE).<BR/>Completeness of follow-up: Follow-up period 3 months. Complete follow-up.<BR/>Outcome definition: All patients were scheduled for bilateral venography. Adequate definitions of VTE and bleeding complications were described in the paper.</P>
<P>Rasmussen et al. trial:<BR/>Randomisation: Computer-generated allocation list.</P>
<P>Concealment: Adequated with sealed envelopes.<BR/>Blinding: Open-label study with assessor-blinded evaluation of the venograms. Patients, healthcare providers and data-analyst were not blinded.</P>
<P>
<BR/>Patients characteristics: Patients undergoing major abdominal surgery for either benign or malignant disease<BR/>ITT-analysis: Patients were included in the final analysis if they have reached an evaluable VTE end point (venogram, autopsy or objective verification of symptomatic VTE).<BR/>Completeness of follow-up: Follow-up period 3 months. Complete follow-up.<BR/>Outcome definition: All patients were scheduled for bilateral venography. Adequate definitions of VTE and bleeding complications were described in the paper.</P>
<P>Jorgensen et al trial:<BR/>Randomisation: Computer-generated allocation</P>
<P>Concealment: , concealment not described in the paper.</P>
<P>
<BR/>Patients characteristics: Patients undergoing major abdominal surgery for malignant disease<BR/>Blinding: Placebo-controlled double-blind study. Patiens, healthcare provides, data collectors, outcome assessors and data analysts were blinded.<BR/>ITT-analysis: The authors defined the ITT-population as patients with an evaluable efficacy end point. Patients were included in the final analysis if they reached an evaluable VTE end point (venogram or objective verification of symptomatic VTE).<BR/>Completeness of follow-up: Follow-up period 90 days.</P>
<P>Early stoppage of a trial: The study was terminated prematurely due to lack of funding.This study was terminated prematurely by the sponsors due to an unexpected high withdrawal rate of patients.<BR/>Outcome definition: All patients were scheduled for bilateral venography. Adequate definitions of VTE and bleeding complications were described. However, the planned interim analysis performed with the 328 patients included in the study did not reveal any significant difference between the two treatment groups. In order to perform a meta-analysis with the results of the study of Lausen et al. (also specifically evaluating the effect of tinzaparin) the venograms were re-evaluated by the same radiologists who assessed the venograms in the study by Lausen et al.</P>
<P>No effort was done in order to rank the studies according to methodological quality.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>No studies reporting on the prolonged use of unfractionated heparin, oral anticoagulants or mechanical methods were identified.<BR/>The search provided the opportunity to compare LMWH with placebo or no treatment with the following out-come parameters: Overall VTE, proximal DVT, all DVT, symptomatic VTE, bleeding complications and mortality.</P>
<P>LMWH versus placebo or no treatment:<BR/>The incidence of VTE after major abdominal or pelvic surgery was 14.3% (95% Confidence Interval 11.2% - 17.8%) in the control group as compared to 6.1% (95% CI 4.0% - 8.7%) in the patients receiving out-of-hospital LMWH. This difference was statistically significant (comparison 01.01), Peto Odds ratio 0.41 (95% CI 0.26 -0.63), P &lt; 0.0001. The number of patients needed to treat (NNT) to avoid 1 case of VTE was 13 (95% CI 9 - 24). Prophylaxis with LMWH as compared to control also offered better protection against all DVT, Peto Odds ratio 0.43 (CI 0.27 - 0.66) (NNT = 14 (95% CI 9 - 27), comparison 01.02) and proximal DVT, Peto Odds ratio 0.27 (0.13 - 0.57) (NNT = 26 (95% CI 17 - 59), comparison 01.03). Interestingly, prolonged thromboprophylaxis with LMWH was associated with a statistically significant reduction of even symptomatic VTE, Peto Odds ratio 0.22 (95% CI 0.06 -0.80), P = 0.02, NNT = 66 (95% CI 36 - 400), comparison 01.04). In none of the analyses were there any statistically significant heterogeneity between the observations made in each individual trial. Exclusion of the unpublished trial did not significantly alter the outcome of this analysis (comparison 01.05 and 01.06). There was no significant difference regarding the incidence of overall (both major and minor) bleeding between the control group (3.7% (95% CI 2.4% - 5.5%)) and the LMWH group (4.1% (95% CI 2.7% - 6.0%)), peto 1.11 (CI 0.62 - 1.97),P = 0.73, NNH = 250 (CI 200 - 333) (comparison 01.07). The number of patients in the safety population are higher than in the other outcome groups as all patients receiving at least one injection of the treatment and patients not reaching an end-point were included in this analysis. There was no difference in mortality between the two groups 5.8 (CI 3.9 - 8.3) versus 5.35 (CI 3.6 - 7.6), Peto Odds ratio 1.12 (95% CI 0.65 - 1.93), P = 0.68 NNH 250 (CI 142 - 333)(comparison 1.08).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-28 14:03:54 +0100" MODIFIED_BY="[Empty name]">
<P>This meta-analysis supports that prolonged thromboprophylaxis with LMWH as compared with in-hospital prophylaxis significantly reduces the risk of major VTE in patients undergoing major abdominal or pelvic surgery. Although the included studies only reported a small number of symptomatic VTE, prolonged administration of LMWH was associated with significantly fewer cases of symptomatic VTE than found in the group allocated to short term thromboprophylaxis. This benefit was archived without a concomitant increase in bleeding complications. The studies included in the present meta-analysis were not designed to detect a reduction of PE or mortality. As such a trial would demand a huge number of patients it is not likely to be performed. In the present meta-analysis there was no significant difference in the mortality rate between the two allocation groups.</P>
<P>The studies included in this meta-analysis were all designed on "surrogate" end points based on mandatory bilateral venography carried out late after surgery. There has been much debate on the clinical relevance of asymptomatic cases of DVT detected in this way. Most of these cases are confined to the lower leg veins and have only a limited potential for progression or embolization. However, even asymptomatic postoperative DVT is associated with a 59% relative risk increment of developing late post-thrombotic syndrome compared with patients without postoperative DVT (<LINK REF="REF-Wille_x002d_J_x00f8_rgensen-2005" TYPE="REFERENCE">Wille-Jørgensen 2005</LINK>). Furthermore, a highly significant association was found between asymptomatic proximal DVT, detected by compression ultrasound, and the 90-days mortality in medical patients (<LINK REF="REF-Vaitkus-2007" TYPE="REFERENCE">Vaitkus 2007</LINK>). This is in agreement with a large autopsy series reporting that fatal PE is seldom preceded by symptomatic DVT (<LINK REF="REF-Lindblad-1991" TYPE="REFERENCE">Lindblad 1991</LINK>). In the published orthopedic studies of extended thromboprophylaxis with LMWH it has been demonstrated, that the relative reduction of asymptomatic DVT as assessed by venography also translated into a corresponding reduction of symptomatic DVT (<LINK REF="REF-Hull-2001" TYPE="REFERENCE">Hull 2001</LINK>; <LINK REF="REF-Eilkelboom-2001" TYPE="REFERENCE">Eilkelboom 2001</LINK>) as observed in the present meta-analysis. Based on these observations it is our opinion that asymptomatic VTE does have clinical importance, thus representing more than a "surrogate" end point.</P>
<P>Compliance in prolonged thromboprophylaxis are an important issue. Two of the included stuides described a very high rate (more than 97% of the patients)of compliance (<LINK REF="STD-Lausen-1998" TYPE="STUDY">Lausen 1998</LINK>; <LINK REF="STD-Rasmussen-2006" TYPE="STUDY">Rasmussen 2006</LINK>) while compliance were not reported in the 2 other studies (<LINK REF="STD-Bergqvist-2002" TYPE="STUDY">Bergqvist 2002</LINK>; <LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>).</P>
<P>The robustness of the outcome in the primary analysis of overall VTE and of symptomatic VTE was demonstrated by the fact that exclusion of the unpublished data (<LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>) and/or of the symptomatic VTE events occurring during the follow-up period of the Bergqvist trial (<LINK REF="STD-Bergqvist-2002" TYPE="STUDY">Bergqvist 2002</LINK>) did not alter the conclusions of this meta-analysis.</P>
<P>There was no significant statistical heterogeneity among the studies, but some differences were identified regarding the design: Two studies were double-blinded and placebo-controlled whereas the other 2 reported assessor-blinded evaluations of the venograms. Although LMWHs belong to the same drug category the single drug differs in terms of anticoagulant profiles and this could cause some bias in the meta-analysis. However, the number of patients included in each trial were to small to make a reliable comparison between the different LMWHs. There were also differences regarding patient characteristics: Two studies included only high risk cancer patients (<LINK REF="STD-Bergqvist-2002" TYPE="STUDY">Bergqvist 2002</LINK>,<LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>) whereas the trials by Lausen and Rasmussen also considered patients subjected to general surgery for benign or malignant disease(<LINK REF="STD-Lausen-1998" TYPE="STUDY">Lausen 1998</LINK>, <LINK REF="STD-Rasmussen-2006" TYPE="STUDY">Rasmussen 2006</LINK>). It was not possible to make a comparison between these 2 patients groups, because no separate data was provided from patients with and without cancer in the two last manuscripts.</P>
<P>
<BR/>It is possible that the increased number of minimally invasive surgical procedures (<LINK REF="REF-Rahr-1999" TYPE="REFERENCE">Rahr 1999</LINK>) and the current trend for fast-track recovery (<LINK REF="REF-Kehlet-2005" TYPE="REFERENCE">Kehlet 2005</LINK>) following gastrointestinal surgery may lower the risk of postoperative VTE. Laparoscopic procedures, however, also cause activation of the coagulation system and cases of VTE have been reported. The fact that these patients are often subjected to a shorter time of sufficient thromboprophylaxis due to early hospital discharge is a potential modern clinical dilemma. In the recently published "Guidelines for DVT prophylaxis during laparoscopic surgery" (<LINK REF="REF-SAGES-2007" TYPE="REFERENCE">SAGES 2007</LINK>) the authors advocate for a patient risk factor stratification in accordance with the American College of Chest Physicians (ACCP) Guidelines (<LINK REF="REF-Geerts-2004" TYPE="REFERENCE">Geerts 2004</LINK>). Until randomised trials including patients undergoing fast track surgery and laparoscopic procedure are available the use of thromboprophylaxis according to ACCP guidelines is recommended.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Administration of LMWH for 4 weeks compared to 5-7 days of after major abdominal or pelvic surgery significantly reduces the incidence of VTE without jeopardizing safety.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Future research of VTE complications should include patients undergoing laparoscopic surgery under fast track regime. Furthemore larger studies including a large number of patients making clinical outcomes measures possible are needed. New antithrombotic drugs with oral administration will soon be available and might ease the implication of prolonged thromboprophylaxis. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-28 14:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>CCCG editorial office for conversion of the review to the required RM5 formate.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-11-07 13:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>MSR is a member the advisory board of Pfizer, Denmark.</P>
<P>All three authors has been investigators on three of the randomised trials included in this review (<LINK REF="STD-Lausen-1998" TYPE="STUDY">Lausen 1998</LINK>; <LINK REF="STD-J_x00f8_rgensen-2002" TYPE="STUDY">Jørgensen 2002</LINK>; <LINK REF="STD-Rasmussen-2006" TYPE="STUDY">Rasmussen 2006</LINK>)</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Morten Schnack Rasmussen came with the idea, structured the work, extracted the data, made the data-entry and the analysis and made the final manuscript.<BR/>Peer Wille-Jørgensen extracted data and proof read the manuscript<BR/>Lars N Jorgensen extracted data and proof read the manuscript</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-10-28 14:04:54 +0100" MODIFIED_BY="[Empty name]">
<P>After recommendation from the editorial team, 'pelvic surgery' has been added to the title</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-04 16:37:22 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-04 16:37:22 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-28 13:50:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-2002" NAME="Bergqvist 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Moigne-Amrani AL, Dietrich-Neto F</AU>
<TI>Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer</TI>
<SO>N Eng J Med</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>13</NO>
<PG>975-980</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-J_x00f8_rgensen-2002" MODIFIED="2008-10-28 13:50:33 +0100" MODIFIED_BY="[Empty name]" NAME="Jørgensen 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Jorgensen LN, Lausen I, Rasmussen MS, Wille-Jørgensen P, Bergqvist D.</AU>
<TI>prolonged thromboprophylaxis with low-molecular weight heparin following major general surgery: an individual patient data meta-analysis.</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<PG>abstract 1952 (poster)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lausen-1998" NAME="Lausen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou, Wille-Jørgensen P</AU>
<TI>Incidence and prevention of deep venous thrombosis occurring late after general surgery: Randomised controlled study of prolonged thromboprophylaxis</TI>
<SO>Eur J Surg</SO>
<YR>1998</YR>
<VL>164</VL>
<PG>657-663</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-2006" NAME="Rasmussen 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olesen B et al</AU>
<TI>Prolonged prophylaxis with dalteparin to prevent late thromboeembolic complications in patients undergoing major abdominal surgery: a multicenter randomised open-label study</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>2384-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-04 16:37:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-2003" MODIFIED="2008-11-04 16:37:22 +0100" MODIFIED_BY="[Empty name]" NAME="Rasmussen 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-04 16:37:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen MS, Wille-Jørgensen P, Jørgensen LN et al.</AU>
<TI>PROLONGED THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN (DALTEPARIN)FOLLOWING MAJOR ABDOMIANL SURGERY PREVENTS LATE VTE: THE FAME STUDY.</TI>
<SO>Pathophysiol Haemost Thromb</SO>
<YR>2003</YR>
<VL>33</VL>
<NO>1</NO>
<PG>77-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-11-04 16:32:36 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-2003a" MODIFIED="2008-11-04 16:37:08 +0100" MODIFIED_BY="[Empty name]" NAME="Rasmussen 2003a" YEAR="2003">
<REFERENCE MODIFIED="2008-11-04 16:37:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen MS</AU>
<TI>DOES PROLONGED THROMBOPROPHYLAXIS IMPROVE OUTCOME IN PATIENTS UNDERGOING SURGERY?</TI>
<SO>Cancer Treat Rev</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>2</NO>
<PG>15-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-28 13:51:24 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-28 13:51:24 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arnesen--2003" NAME="Arnesen  2003" TYPE="JOURNAL_ARTICLE">
<AU>Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T.</AU>
<TI>Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin</TI>
<SO>J Thromb Haemost</SO>
<YR>2003</YR>
<VL>1</VL>
<PG>971-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke_x002d_Pearson-1984" NAME="Clarke-Pearson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT</AU>
<TI>Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy</TI>
<SO>Obstet Gynecol</SO>
<YR>1984</YR>
<VL>63</VL>
<PG>92-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dahl-1995" NAME="Dahl 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dahl OE, Aspelin T, Arnesen H, Sejlefjot I, Kierulf P, Ruyter R, Lyberg T.</AU>
<TI>Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery.</TI>
<SO>Thrombo Res</SO>
<YR>1995</YR>
<VL>80</VL>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eilkelboom-2001" NAME="Eilkelboom 2001" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom JW, Quinlan DJ, Douketis JD</AU>
<TI>Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galster-2000" NAME="Galster 2000" TYPE="JOURNAL_ARTICLE">
<AU>Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V</AU>
<TI>The pre-, peri-, and postsurgical activation of coagulation and the thromboemboloic risk for different risk groups</TI>
<SO>Thrombosis research</SO>
<YR>2000</YR>
<VL>100</VL>
<PG>381-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geerts-2001" NAME="Geerts 2001" TYPE="JOURNAL_ARTICLE">
<AU>Geerts WH, Heit JA, Clagett GP et al</AU>
<TI>Prevention of venous thromboembolism.</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>suppl 1</NO>
<PG>132S- 175S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geerts-2004" NAME="Geerts 2004" TYPE="JOURNAL_ARTICLE">
<AU>Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG</AU>
<TI>Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<PG>338S - 400S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huber-1992" NAME="Huber 1992" TYPE="JOURNAL_ARTICLE">
<AU>Huber O, Bounameaux H, Borst F, Rohner A.</AU>
<TI>Postoperative pulmonary embolism after hospital discharge: an underestimated risk.</TI>
<SO>Arch Surg</SO>
<YR>1992</YR>
<VL>127</VL>
<PG>310-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hull-2001" NAME="Hull 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE</AU>
<TI>Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.</TI>
<SO>Ann Intern Med</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>858 - 69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iversen-2002" NAME="Iversen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Iversen LH, Thorlasius-Ussing O.</AU>
<TI>Relations of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer</TI>
<SO>Thrombosis Haemostasis</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>402-8.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00f8_rgensen-1993" MODIFIED="2008-10-28 13:51:24 +0100" MODIFIED_BY="[Empty name]" NAME="Jørgensen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jørgensen LN, Wille-Jørgensen P, Hauch O</AU>
<TI>Prophylaxis of postoperative thromboembolism with low molecular weight heparins</TI>
<SO>Br J Surg</SO>
<YR>1993</YR>
<VL>80</VL>
<PG>689 - 704</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kehlet-2005" NAME="Kehlet 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kehlet H</AU>
<TI>Fast-track colonic surgery: status and perspectives</TI>
<SO>Recent Results Cancer Res</SO>
<YR>2005</YR>
<VL>165</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiil-1978" NAME="Kiil 1978" TYPE="JOURNAL_ARTICLE">
<AU>Kiil J, Kiil J, Axelsen F, Andersen D</AU>
<TI>Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin.</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>May 27</VL>
<NO>1(8074</NO>
<PG>1115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindblad-1991" NAME="Lindblad 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lindblad B, Sternby NH, Bergqvist D</AU>
<TI>Incidence of venous thromboembolism verified by necropsy over 30 years</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<PG>709-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rahr-1994" NAME="Rahr 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C, Nieuwenhuizen W</AU>
<TI>Haemostatic activation before and after surgery in patients with and without gastric malignancy.</TI>
<SO>Thromb Haemost</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>713-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rahr-1999" NAME="Rahr 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rahr HB, Fabrin K, Larsen JF, Thorlacius-Ussing O</AU>
<TI>Coagulation and fibrinolysis during laparoscopic Cholecystectomy</TI>
<SO>Throm Res</SO>
<YR>1999</YR>
<VL>93</VL>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SAGES-2007" NAME="SAGES 2007" TYPE="JOURNAL_ARTICLE">
<AU>Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee</AU>
<TI>Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery</TI>
<SO>Surg Endosc</SO>
<YR>2007</YR>
<VL>April 5</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scurr-1988" NAME="Scurr 1988" TYPE="JOURNAL_ARTICLE">
<AU>Scurr JH, Colerigde-Smith PD, Hasty JH.</AU>
<TI>Deep Venous thrombosis: a continuing problem.</TI>
<SO>BMJ</SO>
<YR>1988</YR>
<VL>297</VL>
<PG>28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-S_x00f8_rensen-1990" NAME="Sørensen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Sørensen C, Andersen M, Kristiansen VB, Jensen R, Wille-Jørgensen P.</AU>
<TI>The occurrence of late thromboembolic complications after elective abdominal surgery</TI>
<SO>Ugskr laeg</SO>
<YR>1990</YR>
<VL>152</VL>
<PG>1586-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaitkus-2007" NAME="Vaitkus 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group</AU>
<TI>Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients</TI>
<SO>Thromb Haemost</SO>
<YR>2005</YR>
<VL>93</VL>
<PG>76-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_J_x00f8_rgensen-1992" NAME="Wille-Jørgensen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jørgensen P, Jørgensen LN, Hauch O, Borris LC, Lassen MR, Nehen AM, Kjær L, Jensen R</AU>
<TI>Potential influence of observer variation on thromboprophylactic studies</TI>
<SO>Hæmostasis</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_J_x00f8_rgensen-2005" NAME="Wille-Jørgensen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jørgensen P, Jorgensen LN, Crawford M</AU>
<TI>Asymptomatic postoperative deep vein thrombosis and the developement of postthrombotic syndrome. A systematic review and meta-analysis</TI>
<SO>Thromb Haemost</SO>
<YR>2005</YR>
<VL>93</VL>
<PG>236-41</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-06 11:32:08 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bergqvist-2002">
<CHAR_METHODS>
<P>RCT, double-blinded, venography</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients undergoing surgery for abdominal or pelvic cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH (enoxaparin 40 mg) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LMWH 165<BR/>Placebo167</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-J_x00f8_rgensen-2002">
<CHAR_METHODS>
<P>RCT, double-blinded, venography</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients undergoing curative surgery for abdominal or pelvic cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH (tinzaparin 3500 IE) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LMWH 58<BR/>Placebo 50</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lausen-1998">
<CHAR_METHODS>
<P>RCT, assessor-blinded, venography</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Patients undergoing major abdominal or non cardiac thoracis surgery for either malignant or benign diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH (tinzaparin 3500 IE) or no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LMWH 58<BR/>Control 60</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-2006">
<CHAR_METHODS>
<P>RCT, assessor blinded, venography</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-28 13:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Patients undergoing major abdominal surgery for either malignant or benign diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH (dalteparin 5000 IE) or no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LMWH 165<BR/>Control 178</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-06 11:32:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-06 11:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-06 11:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Double publication. Data included in the Rasmussen 2006 trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-06 11:32:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-06 11:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>Review, and not a primary trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-23 21:39:05 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-23 21:39:05 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bergqvist-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-J_x00f8_rgensen-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lausen-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rasmussen-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>LMWH versus placebo</NAME>
<DICH_OUTCOME CHI2="0.3153765276121754" CI_END="0.6253288235703536" CI_START="0.26376044927860354" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.40612437928764766" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.20389155272177542" LOG_CI_START="-0.5787903261050756" LOG_EFFECT_SIZE="-0.3913409394134255" METHOD="PETO" NO="1" P_CHI2="0.9571111034100098" P_Q="1.0" P_Z="4.279516062670311E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="455" WEIGHT="99.99999999999997" Z="4.091846660390017">
<NAME>All VTE</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.863140748926482" CI_START="0.18393108927040497" EFFECT_SIZE="0.3984450001489804" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.06391837983750427" LOG_CI_START="-0.7353448571815631" LOG_EFFECT_SIZE="-0.39963161850953366" ORDER="1" O_E="-5.91566265060241" SE="0.39439923640656555" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="6.428769714317541" WEIGHT="31.176769500098626"/>
<DICH_DATA CI_END="0.970628255018675" CI_START="0.10316181755551855" EFFECT_SIZE="0.31643605192592683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.012947070510852449" LOG_CI_START="-0.9864810148534234" LOG_EFFECT_SIZE="-0.49971404268213804" ORDER="2" O_E="-3.518518518518518" SE="0.5718586579775717" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="58" TOTAL_2="50" VAR="3.0578952091586222" WEIGHT="14.829477229379146"/>
<DICH_DATA CI_END="1.9631162646962885" CI_START="0.1308971151859998" EFFECT_SIZE="0.5069183916800216" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2929460212611333" LOG_CI_START="-0.8830699246685509" LOG_EFFECT_SIZE="-0.29506195170370875" ORDER="3" O_E="-1.4237288135593218" SE="0.6907975880119147" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="2.0955516761319695" WEIGHT="10.16252478865581"/>
<DICH_DATA CI_END="0.8166452426714521" CI_START="0.2216997506526119" EFFECT_SIZE="0.4254997610714989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.08796656355302358" LOG_CI_START="-0.6542347953395291" LOG_EFFECT_SIZE="-0.37110067944627634" ORDER="4" O_E="-7.723032069970845" SE="0.3326287624243481" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="9.038167800055861" WEIGHT="43.83122848186639"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.46664530324076914" CI_END="0.6588340329638436" CI_START="0.27447876140096367" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.42524810327233376" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.18122397485346028" LOG_CI_START="-0.5614912547228699" LOG_EFFECT_SIZE="-0.3713576147881651" METHOD="PETO" NO="2" P_CHI2="0.9261557847932482" P_Q="1.0" P_Z="1.291446692707152E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="455" WEIGHT="100.0" Z="3.828084028788689">
<NAME>All DVT</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.863140748926482" CI_START="0.18393108927040497" EFFECT_SIZE="0.3984450001489804" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.06391837983750427" LOG_CI_START="-0.7353448571815631" LOG_EFFECT_SIZE="-0.39963161850953366" ORDER="5" O_E="-5.91566265060241" SE="0.39439923640656555" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="6.428769714317541" WEIGHT="32.07605794748807"/>
<DICH_DATA CI_END="0.970628255018675" CI_START="0.10316181755551855" EFFECT_SIZE="0.31643605192592683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.012947070510852449" LOG_CI_START="-0.9864810148534234" LOG_EFFECT_SIZE="-0.49971404268213804" ORDER="6" O_E="-3.518518518518518" SE="0.5718586579775717" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="58" TOTAL_2="50" VAR="3.0578952091586222" WEIGHT="15.257230898763115"/>
<DICH_DATA CI_END="1.9631162646962885" CI_START="0.1308971151859998" EFFECT_SIZE="0.5069183916800216" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2929460212611333" LOG_CI_START="-0.8830699246685509" LOG_EFFECT_SIZE="-0.29506195170370875" ORDER="7" O_E="-1.4237288135593218" SE="0.6907975880119147" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="2.0955516761319695" WEIGHT="10.45566103353577"/>
<DICH_DATA CI_END="0.9338392111200666" CI_START="0.24264741520130784" EFFECT_SIZE="0.4760185613943143" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.029727894363717103" LOG_CI_START="-0.6150243306408361" LOG_EFFECT_SIZE="-0.32237611250227655" ORDER="8" O_E="-6.279883381924197" SE="0.3438060239332657" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="8.460052075807416" WEIGHT="42.211050120213045"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3370836362589307" CI_END="0.5727351646867573" CI_START="0.12637254029106149" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.26903159233719187" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.2420461513365075" LOG_CI_START="-0.8983472844052162" LOG_EFFECT_SIZE="-0.5701967178708618" METHOD="PETO" NO="3" P_CHI2="0.952909617046236" P_Q="1.0" P_Z="6.600743839855049E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="455" WEIGHT="100.0" Z="3.405647117823387">
<NAME>Proximal DVT</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.643010016418181" CI_START="0.05151065020949207" EFFECT_SIZE="0.3689758318046058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42209880901400376" LOG_CI_START="-1.2881029680652132" LOG_EFFECT_SIZE="-0.43300207952560477" ORDER="9" O_E="-0.9879518072289157" SE="1.0045809894916606" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="0.9909005950639818" WEIGHT="14.726908935057516"/>
<DICH_DATA CI_END="1.4673417899399563" CI_START="0.04076574553045798" EFFECT_SIZE="0.24457571836733713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.1665312864374728" LOG_CI_START="-1.3897046108205515" LOG_EFFECT_SIZE="-0.6115866621915392" ORDER="10" O_E="-1.6851851851851851" SE="0.9141406695412951" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="58" TOTAL_2="50" VAR="1.1966687178698256" WEIGHT="17.785064739377855"/>
<DICH_DATA CI_END="2.226673348702316" CI_START="0.008499481825070676" EFFECT_SIZE="0.13757023536239443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3476565110344114" LOG_CI_START="-2.0706075504471397" LOG_EFFECT_SIZE="-0.8614755197063642" ORDER="11" O_E="-0.9830508474576272" SE="1.4205002803144269" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="0.4955840865062353" WEIGHT="7.365442858745825"/>
<DICH_DATA CI_END="0.7367728325388548" CI_START="0.10493410970052021" EFFECT_SIZE="0.27805143630989426" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.13266639651369094" LOG_CI_START="-0.9790833178426303" LOG_EFFECT_SIZE="-0.5558748571781607" ORDER="12" O_E="-5.177842565597668" SE="0.4971894894199522" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="4.045350181546566" WEIGHT="60.12258346681881"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30416766790931127" CI_END="0.8015262764340916" CI_START="0.05804043233631022" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.21568711508374247" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.09608223560144837" LOG_CI_START="-1.236269361214065" LOG_EFFECT_SIZE="-0.6661757984077566" METHOD="PETO" NO="4" P_CHI2="0.858916286462936" P_Q="1.0" P_Z="0.022004410903374676" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="446" TOTAL_2="455" WEIGHT="100.0" Z="2.2902917300524392">
<NAME>Symptomatic VTE</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7528438321061144" CI_START="0.05149382145373143" EFFECT_SIZE="0.30043406485741037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24374322477846094" LOG_CI_START="-1.2882448771631612" LOG_EFFECT_SIZE="-0.5222508261923501" ORDER="13" O_E="-1.4849397590361444" SE="0.899897394543918" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="1.2348494458304955" WEIGHT="55.391290186623955"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="14" O_E="0.0" SE="0.0" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="58" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.0556200537741285" CI_START="0.0027748521753861097" EFFECT_SIZE="0.13992248802430937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8485351859287372" LOG_CI_START="-2.5567601480815276" LOG_EFFECT_SIZE="-0.8541124810763953" ORDER="15" O_E="-0.4915254237288136" SE="2.000287335681391" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="0.24992818155702384" WEIGHT="11.210957317253923"/>
<DICH_DATA CI_END="1.3953548213716696" CI_START="0.014850057954058003" EFFECT_SIZE="0.14394825446612242" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.14468465733696123" LOG_CI_START="-1.828271851459329" LOG_EFFECT_SIZE="-0.8417935970611841" ORDER="16" O_E="-1.4431486880466473" SE="1.1589244195591684" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="0.7445429781987546" WEIGHT="33.39775249612212"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09180953635035505" CI_END="0.6770834966688009" CI_START="0.2657141535692933" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4241587771260755" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1693577716301646" LOG_CI_START="-0.5755853117796669" LOG_EFFECT_SIZE="-0.3724715417049158" METHOD="PETO" NO="5" P_CHI2="0.9551329185453251" P_Q="1.0" P_Z="3.2539416431417106E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="388" TOTAL_2="405" WEIGHT="99.99999999999999" Z="3.594196527094512">
<NAME>All VTE (Sensitivity analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.863140748926482" CI_START="0.18393108927040497" EFFECT_SIZE="0.3984450001489804" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.06391837983750427" LOG_CI_START="-0.7353448571815631" LOG_EFFECT_SIZE="-0.39963161850953366" ORDER="17" O_E="-5.91566265060241" SE="0.39439923640656555" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="6.428769714317541" WEIGHT="36.60511698872993"/>
<DICH_DATA CI_END="1.9631162646962885" CI_START="0.1308971151859998" EFFECT_SIZE="0.5069183916800216" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2929460212611333" LOG_CI_START="-0.8830699246685509" LOG_EFFECT_SIZE="-0.29506195170370875" ORDER="18" O_E="-1.4237288135593218" SE="0.6907975880119147" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="2.0955516761319695" WEIGHT="11.931974183163431"/>
<DICH_DATA CI_END="0.8166452426714521" CI_START="0.2216997506526119" EFFECT_SIZE="0.4254997610714989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.08796656355302358" LOG_CI_START="-0.6542347953395291" LOG_EFFECT_SIZE="-0.37110067944627634" ORDER="19" O_E="-7.723032069970845" SE="0.3326287624243481" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="9.038167800055861" WEIGHT="51.46290882810662"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.129861377408951E-4" CI_END="0.821153565950161" CI_START="0.024454824233939146" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.14170803126281709" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.08557561680482499" LOG_CI_START="-1.6116354542700002" LOG_EFFECT_SIZE="-0.8486055355374126" METHOD="PETO" NO="6" P_CHI2="0.9997435398254764" P_Q="1.0" P_Z="0.029273877094229992" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="388" TOTAL_2="405" WEIGHT="100.0" Z="2.1797785983246007">
<NAME>Symptomatic VTE (Sensitivity analysis)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.903131474250198" CI_START="0.0027175540496532347" EFFECT_SIZE="0.13696580921214363" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8390461448641326" LOG_CI_START="-2.565821809437541" LOG_EFFECT_SIZE="-0.8633878322867043" ORDER="20" O_E="-0.49698795180722893" SE="2.0000362907250007" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="0.24999092756568442" WEIGHT="20.08827188168956"/>
<DICH_DATA CI_END="7.0556200537741285" CI_START="0.0027748521753861097" EFFECT_SIZE="0.13992248802430937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8485351859287372" LOG_CI_START="-2.5567601480815276" LOG_EFFECT_SIZE="-0.8541124810763953" ORDER="21" O_E="-0.4915254237288136" SE="2.000287335681391" STUDY_ID="STD-Lausen-1998" TOTAL_1="58" TOTAL_2="60" VAR="0.24992818155702384" WEIGHT="20.083229863190176"/>
<DICH_DATA CI_END="1.3953548213716696" CI_START="0.014850057954058003" EFFECT_SIZE="0.14394825446612242" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.14468465733696123" LOG_CI_START="-1.828271851459329" LOG_EFFECT_SIZE="-0.8417935970611841" ORDER="22" O_E="-1.4431486880466473" SE="1.1589244195591684" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="0.7445429781987546" WEIGHT="59.828498255120266"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0934766336765227" CI_END="1.9723730298263464" CI_START="0.6216671933462525" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1073209135946043" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.29498905536910064" LOG_CI_START="-0.20644205063832174" LOG_EFFECT_SIZE="0.044273502365389426" METHOD="PETO" NO="7" P_CHI2="0.7786491095211202" P_Q="1.0" P_Z="0.7292621171214123" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="614" TOTAL_2="628" WEIGHT="99.99999999999999" Z="0.34610724809851656">
<NAME>Bleeding complications</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3624723033661907" CI_START="0.6094989725711132" EFFECT_SIZE="1.4315807396722402" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5266587157480793" LOG_CI_START="-0.21502702213267422" LOG_EFFECT_SIZE="0.15581584680770263" ORDER="23" O_E="1.8902195608782435" SE="0.4356698738347688" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="253" TOTAL_2="248" VAR="5.268475201294019" WEIGHT="45.70699689054517"/>
<DICH_DATA CI_END="4.130880164086983" CI_START="0.36364556602089426" EFFECT_SIZE="1.2256330019356918" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6160425963731867" LOG_CI_START="-0.43932170347106564" LOG_EFFECT_SIZE="0.08836044645106049" ORDER="24" O_E="0.5294117647058822" SE="0.6199262138660518" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="93" TOTAL_2="94" VAR="2.602076124567474" WEIGHT="22.57447948229035"/>
<DICH_DATA CI_END="4.407598699348389" CI_START="0.12571915396070388" EFFECT_SIZE="0.7443920871962424" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6442020462356672" LOG_CI_START="-0.9005985502716554" LOG_EFFECT_SIZE="-0.1281982520179941" ORDER="25" O_E="-0.358490566037736" SE="0.9074235172746814" STUDY_ID="STD-Lausen-1998" TOTAL_1="75" TOTAL_2="84" VAR="1.2144508383991781" WEIGHT="10.53604668781536"/>
<DICH_DATA CI_END="2.438581568277011" CI_START="0.19844865487684593" EFFECT_SIZE="0.695653097478939" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3871372869155436" LOG_CI_START="-0.7023518404783755" LOG_EFFECT_SIZE="-0.15760727678141595" ORDER="26" O_E="-0.8860759493670889" SE="0.6399713064893469" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="193" TOTAL_2="202" VAR="2.4416251788362047" WEIGHT="21.182476939349108"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4657804724217414" CI_END="1.9261586188494983" CI_START="0.6517685021291899" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.120450586983097" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" I2="13.439410722291756" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2846920483412449" LOG_CI_START="-0.18590663141616254" LOG_EFFECT_SIZE="0.04939270846254115" METHOD="PETO" NO="8" P_CHI2="0.32522758793627426" P_Q="1.0" P_Z="0.6807612419111775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="498" TOTAL_2="523" WEIGHT="100.0" Z="0.411424569807003">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9191698812683358" CI_START="0.13620348495719437" EFFECT_SIZE="0.5112705996374447" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2831134193586891" LOG_CI_START="-0.865811780247635" LOG_EFFECT_SIZE="-0.29134918044447294" ORDER="27" O_E="-1.4728915662650603" SE="0.6748843495202159" STUDY_ID="STD-Bergqvist-2002" TOTAL_1="165" TOTAL_2="167" VAR="2.195539656898624" WEIGHT="16.777138851854815"/>
<DICH_DATA CI_END="121.6259420876421" CI_START="0.46873999633759306" EFFECT_SIZE="7.550559161328229" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0850262172384215" LOG_CI_START="-0.3290679877052733" LOG_EFFECT_SIZE="0.8779791147665741" ORDER="28" O_E="1.0053475935828877" SE="1.4180508859429672" STUDY_ID="STD-J_x00f8_rgensen-2002" TOTAL_1="93" TOTAL_2="94" VAR="0.4972976064514284" WEIGHT="3.8000821200907606"/>
<DICH_DATA CI_END="3.414358021629977" CI_START="0.23261158008401606" EFFECT_SIZE="0.8911897746181137" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.533309058274328" LOG_CI_START="-0.633368668621316" LOG_EFFECT_SIZE="-0.05002980517349398" ORDER="29" O_E="-0.2452830188679247" SE="0.6853122719263898" STUDY_ID="STD-Lausen-1998" TOTAL_1="75" TOTAL_2="84" VAR="2.1292319894011564" WEIGHT="16.270451149333848"/>
<DICH_DATA CI_END="2.580848627598199" CI_START="0.6600539201192035" EFFECT_SIZE="1.3051816938190859" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.4117625329721215" LOG_CI_START="-0.18042058528581909" LOG_EFFECT_SIZE="0.11567097384315125" ORDER="30" O_E="2.201166180758019" SE="0.34785129501842593" STUDY_ID="STD-Rasmussen-2006" TOTAL_1="165" TOTAL_2="178" VAR="8.264427058006175" WEIGHT="63.15232787872058"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>